Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. Study

Atherosclerosis

Volumn 120, Issue 1-2, 1996, Pages 25-35

  Violi, F ^a   Criqui, M ^b   Longoni, A ^c   Castiglioni, C ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

Author keywords

Cardiovascular disease; Cerebrovascular disease; Fibrinogen; Peripheral vascular disease; Risk factors; White blood cells

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; ITALY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0030061777     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05657-2     Document Type: Article

References (23)

1. Coffmann JD. Intermittent claudication. Be conservative. N Engl J Med 1991;325:577.
2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, Mc Cann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381.
3. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, Bousser MG, Clement D, Coffmann J, Deutshinoff A, Blétry O, Hampton J, Mahler F, Ohlin P, Rieger, Stranden E, Turpie AGG, Urai L, Verstraete M. Fate of the patients with chronic leg ischaemia. J Cardiovasc Surg 1989;30:50.
4. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Prevention of atherosclerotic complications: controlled trial of ketanserin. Br Med J 1989;298:424.
5. Schadt DC, Hines EA Jr, Juergens JL, Barker NW. Chronic atherosclerotic occlusion of the femoral artery. J Am Med Assoc 1961;175:937.
6. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987;221:253.
7. Jeurgens JL, Barker NW, Hines EA. Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960;XXI:188.
8. Szilagyi DE, Hageman JH, Smith RF, Elliott JP, Brown F, Dietz P. Autogenous vein grafting in femoropoplitean atherosclerosis: the limits of its effectiveness. Surgery 1979;86;836.
9. Dormandy J, Murray G. The fate of the claudicant. A prospective study of 1969 claudicants. Eur J Vasc Surg 1991;5:131.
10. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, De Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E, the PLAT Group. The PLAT Group: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atheroscler Thromb 1991;12:1063.
11. Balsano F, Violi F, The ADEP Group. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation 1993;87:1563.
12. Violi F, Ghiselli A, Iuliano L, Pratico' D, Alessandri C, Balsano F. Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmac 1988;33:599.
13. 2 receptor antagonist in human platelets. Thromb Haemostas 1989;61:479.
14. Chuang Stein C. Summarizing laboratory data with different reference ranges in multicentre clinical trials. Drug Inf J 1992;26:77.
15. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chron Dis 1967;20:511.
16. Hosmer DW Jr, Lemeshow S. Applied Logistic Regression, 1989; J. Wiley, New York.
17. Simon R. Confidence intervals for reporting results of clinical trials. Ann Int Med 1986;105:429.
18. Newman AB, Siscovich DS, Menolio TA, Polak J, Fried LP, Borheni NO, Woljson SK, for the Cardiovascular Health Study (CHS) Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993;88:837.
19. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991;83:836.
20. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801.
21. Kannel FB. Fibrinogen: a major cardiovascular risk factor. In: Ernst E, Koenig W and Lowe GDO (eds). Fibrinogen: a New Cardiovascular Risk Factor. Blackwell, MZV, 1992;101.
22. Banerjee AK, Pearson J, Gilliland EL, Gors D, Lewis JD, Stirling Y, Meede TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemostas 1992;68:261.
23. Eriksson H, Wilhelmsen, Welin L, Larsson B, Svardsudd Tibblin G. Twenty-one year follow-up of CVD and total mortality among men born in 1913. In: Ernst E, Koenig W and Lowe GDO. (eds). Fibrinogen: A New Cardiovascular Risk Factor. Blackwell, MZV, 1992:115.